APA (7th ed.) Citation

Chavez-Tapia, N., Sayeed, M. A., Luxmi, S., Kasper, D. J., Xue, F., Shen, Y., . . . Du, B. Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial. Elsevier.

Chicago Style (17th ed.) Citation

Chavez-Tapia, Norberto, Muneeba Ahsan Sayeed, Shobha Luxmi, Douglas J. Kasper, Fenchao Xue, Yang Shen, Weiliang Fan, Wei Yuan, and Bin Du. Safety and Efficacy of Selective RIPK1 Inhibitor SIR1-365 in Hospitalized Patients with Severe COVID-19: A Multicenter, Randomized, Double-blind, Phase 1b Trial. Elsevier.

MLA (9th ed.) Citation

Chavez-Tapia, Norberto, et al. Safety and Efficacy of Selective RIPK1 Inhibitor SIR1-365 in Hospitalized Patients with Severe COVID-19: A Multicenter, Randomized, Double-blind, Phase 1b Trial. Elsevier.